Astellas Venture Management

Astellas Venture Management

A Menlo Park-based venture capital firm that invests in companies within the biotechnology sector

Astellas Venture Management is a venture capital firm in Menlo Park that prefers to invest in companies within the biotechnology sector. Founded 1999 in Menlo Park, California, the firm invests in early stage ventures, late stage ventures, and private equity. The notable investment portfolio of Astellas Venture Management includes TScan Therapeutics, Heartseed, CODA Biotherapeutics, Oncorus, Cleave Therapeutics, Twentyeight-Seven Therapeutics, Effector Therapeutics, and Oncorus. As of January 2020, Astellas Venture Management has made 41 investments and 9 exits. Their most recent investment was on Jan 10, 2020, when TScan Therapeutics raised $35M.

Timeline

1999

Founded

Funded Companies

Company
Description
Industry
Website
Location
Fate Therapeutics

A company developing therapies for the treatment of cancer and immune disorders

Biotechnology
California
Epizyme

A biopharmaceutical company focused on the discovery and development of epigenetic medicines to treat cancer and other disease

Biotechnology
Cambridge, Massachusetts
PhaseBio Pharmaceuticals

A biopharmaceutical company that develops drugs for the treatment of cardiovascular diseases, endocrine and other metabolic disorders

Biotechnology
Malvern, Arkansas
Effector Therapeutics

A company dedicated on the discovery and development of small molecule therapeutics to treat cancer

Biotechnology
San Diego
Verastem

A biopharmaceutical company that develops therapeutics to treat cancer

Biotechnology
Boston
Nereus Pharmaceuticals

A company developing biologically active compounds and drug candidates

Biotechnology
San Diego
DecImmune Therapeutics

A biotechnology company developing peptides and antibodies for inflammation and autoimmunity

Biotechnology
Boston
Intradigm

A biotechnology company that develops RNA interference therapeutics

Biotechnology
Palo Alto, California
Inimex Pharmaceuticals

A company developing Innate Defense Regulators

Biotechnology
Twentyeight-Seven Therapeutics

Twentyeight-Seven is a biomedical startup with a passion for cutting-edge life saving technology.

Biotechnology
Cambridge, Cambridgeshire
Viamet Pharmaceuticals

A company developing antifungal therapies

Biotechnology
Bicycle Therapeutics

Biotechnology
Cambridge, Massachusetts
Oncorus

Oncorus is a Cambridge, Massachusetts-based company.

Cambridge, Massachusetts
F2G

F2G is a biotechnology company.

Biotechnology
Cleave Biosciences

Cleave Biosciences is a Burlingame, California-based company.

Burlingame, California
Cleave Therapeutics, Inc

Lectus Therapeutics

17 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Takashi Futami

Associate Investment Director

Ken Shimokawa

Senior Investment Director

Makoto Ohori

Investment Director

Sakae Asanuma

President & Chief Executive Officer

Takatoshi Soga

Associate Investment Director

Taro Masunaga

Investment Director

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Cleave Therapeutics

Twentyeight-Seven Therapeutics

CODA Biotherapeutics

Effector Therapeutics

Heartseed

Oncorus

TScan Therapeutics

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.